Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Investor FAQs

Show all

Spectrum Pharmaceuticals, Inc. was added to the Russell 2000®, Russell 3000®, and the Russell Global® indexes on July 1, 2009. We are also a member of the Nasdaq Biotechnology Index.
Spectrum Pharmaceuticals, Inc.'s ticker symbol is SPPI and is traded on the Nasdaq Global Market System.
Spectrum Pharmaceuticals, Inc. can be found under the CUSIP number 847 63A 10 8.
Spectrum's transfer agent is Computershare and can be contacted at:
Computershare Trust Company, N.A.
P.O. Box 43070
Providence, Rhode Island 02940-3070
Inside the US 800.962.4284
Outside the US 781.575.3210
Questions regarding stock certificates and other pertinent information should be relayed to our transfer agent or a registered broker.
Investor inquiries regarding Spectrum Pharmaceuticals, Inc. should be directed to:

Investor Relations
Phone: (949)788-6700


ir@sppirx.com

All other inquiries can be directed to:

Tel: (949) 788-6700 or info@sppirx.com
 
For financial information, please contact Investor Relations at:

ir@sppirx.com or (949) 743-9216
 
The Annual Meeting of Stockholders typically takes place in the middle of each year. Further information regarding the date will be available on our website once the date has been set.
Our auditors are Deloitte & Touche LLP ("D&T")
Spectrum currently has three drug candidates that are no longer under active development; SPI-339, SPI-376 and SPI-392. Spectrum still retains the intellectual property rights to these products, and intends to out-license these compounds if possible. Currently, there are no plans to resurrect these products into active development.
For a list of links to current clinical trials click here.

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Copyright West LLC. Minimum 15 minutes delayed.